Literature DB >> 21934349

Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study.

Annekathrin Roth, Eberhard Schleyer, Konrad Schoppmeyer, Regine Kluge, Christian Wittekind, Joachim Mössner, Marcus Wiedmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21934349     DOI： 10.1159/000331065

Source DB:  PubMed          Journal:  Onkologie        ISSN： 0378-584X


× No keyword cloud information.
  10 in total

Review 1.  Therapeutic options for intrahepatic cholangiocarcinoma.

Authors:  Manojkumar Bupathi; Daniel H Ahn; Tanios Bekaii-Saab
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

2.  Second-line systemic treatment for advanced cholangiocarcinoma.

Authors:  Jane E Rogers; Lindsey Law; Van D Nguyen; Wei Qiao; Milind M Javle; Ahmed Kaseb; Rachna T Shroff
Journal:  J Gastrointest Oncol       Date:  2014-12

3.  A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin.

Authors:  Shengli He; Jie Shen; Xianjun Sun; Luming Liu; Jingcheng Dong
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

4.  Activation of abl family kinases in solid tumors.

Authors:  Sourik S Ganguly; Rina Plattner
Journal:  Genes Cancer       Date:  2012-05

5.  Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma.

Authors:  Matthias Unseld; Werner Scheithauer; Roman Weigl; Gabriela Kornek; Nadja Stranzl; Daniela Bianconi; Georg Brunauer; Guenther Steger; Christoph C Zielinski; Gerald W Prager
Journal:  J Gastrointest Oncol       Date:  2016-08

Review 6.  Current status of chemotherapy for the treatment of advanced biliary tract cancer.

Authors:  Takashi Sasaki; Hiroyuki Isayama; Yousuke Nakai; Kazuhiko Koike
Journal:  Korean J Intern Med       Date:  2013-08-14       Impact factor: 2.884

7.  Curative resection of gallbladder cancer with liver invasion and hepatic metastasis after chemotherapy with gemcitabine plus S-1: report of a case.

Authors:  Takashi Okumura; Jun Nakamura; Keita Kai; Yasushi Ide; Hiroaki Nakamura; Hiroki Koga; Takao Ide; Atsushi Miyoshi; Kenji Kitahara; Hirokazu Noshiro
Journal:  World J Surg Oncol       Date:  2014-11-04       Impact factor: 2.754

8.  Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial.

Authors:  Seung Tae Kim; Sung Yong Oh; Jeeyun Lee; Jung Hun Kang; Hyun Woo Lee; Myung Ah Lee; Byeong Seok Sohn; Ji Hyong Hong; Young Suk Park; Joon Oh Park; Ho Yeong Lim
Journal:  J Cancer       Date:  2019-10-15       Impact factor: 4.207

9.  Comparative Proteomic Analysis of the Mesenchymal Stem Cells Secretome from Adipose, Bone Marrow, Placenta and Wharton's Jelly.

Authors:  Sungho Shin; Jeongmin Lee; Yumi Kwon; Kang-Sik Park; Jae-Hoon Jeong; Suk-Joo Choi; Sa Ik Bang; Jong Wook Chang; Cheolju Lee
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

10.  Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures.

Authors:  Alice Fraveto; Vincenzo Cardinale; Maria Consiglia Bragazzi; Felice Giuliante; Agostino Maria De Rose; Gian Luca Grazi; Chiara Napoletano; Rossella Semeraro; Anna Maria Lustri; Daniele Costantini; Lorenzo Nevi; Sabina Di Matteo; Anastasia Renzi; Guido Carpino; Eugenio Gaudio; Domenico Alvaro
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.